CN113424064B - 表征化合物的凝聚物缔合特征的方法及其用途 - Google Patents

表征化合物的凝聚物缔合特征的方法及其用途 Download PDF

Info

Publication number
CN113424064B
CN113424064B CN202080013006.6A CN202080013006A CN113424064B CN 113424064 B CN113424064 B CN 113424064B CN 202080013006 A CN202080013006 A CN 202080013006A CN 113424064 B CN113424064 B CN 113424064B
Authority
CN
China
Prior art keywords
target
coacervate
test compound
determining
condensate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080013006.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113424064A (zh
Inventor
B·A·比特尔
P·J·达恩德里克尔
S·P·哈雷
M·A·穆科
E·E·博泽克
M·米塔施
D·M·密特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dew Point Therapy
Original Assignee
Dew Point Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dew Point Therapy filed Critical Dew Point Therapy
Publication of CN113424064A publication Critical patent/CN113424064A/zh
Application granted granted Critical
Publication of CN113424064B publication Critical patent/CN113424064B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/26—Mass spectrometers or separator tubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202080013006.6A 2019-02-08 2020-02-07 表征化合物的凝聚物缔合特征的方法及其用途 Active CN113424064B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962803365P 2019-02-08 2019-02-08
US62/803,365 2019-02-08
US201962866526P 2019-06-25 2019-06-25
US62/866,526 2019-06-25
PCT/US2020/017333 WO2020163795A1 (en) 2019-02-08 2020-02-07 Methods of characterizing condensate-associated characteristics of compounds and uses thereof

Publications (2)

Publication Number Publication Date
CN113424064A CN113424064A (zh) 2021-09-21
CN113424064B true CN113424064B (zh) 2025-03-04

Family

ID=69771186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080013006.6A Active CN113424064B (zh) 2019-02-08 2020-02-07 表征化合物的凝聚物缔合特征的方法及其用途

Country Status (10)

Country Link
US (3) US11493519B2 (https=)
EP (1) EP3921650A1 (https=)
JP (2) JP7564110B2 (https=)
KR (1) KR20210124374A (https=)
CN (1) CN113424064B (https=)
AU (1) AU2020219368A1 (https=)
CA (1) CA3127237A1 (https=)
IL (1) IL285117A (https=)
SG (1) SG11202106690QA (https=)
WO (1) WO2020163795A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
EP3921650A1 (en) 2019-02-08 2021-12-15 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
WO2022187202A1 (en) * 2021-03-02 2022-09-09 Dewpoint Therapeutics, Inc. New condensate paradigms
EP4220159A1 (en) * 2022-01-27 2023-08-02 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Drug discovery assay to screen for compounds
EP4063857A1 (en) * 2021-03-26 2022-09-28 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Drug discovery assay to screen for compounds
EP4314815A1 (en) * 2021-03-26 2024-02-07 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Drug discovery assay to screen for compounds
CA3244504A1 (en) * 2021-12-31 2023-07-06 Laboratory Corporation Of America Holdings METHODS AND SYSTEMS FOR HYDROPHILIC PHASE EXTRACTION
KR20250022285A (ko) 2023-08-07 2025-02-17 포항공과대학교 산학협력단 액체-액체 상분리를 통한 scotin 프롤린-풍부 도메인 생체분자 응축물 및 그의 응용
WO2025050003A1 (en) * 2023-09-01 2025-03-06 Transition Bio, Inc. High-throughput condensate modulator screen

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239907T1 (de) 1999-02-26 2003-05-15 Cellomics Inc Ein system für zellbasierte reihenuntersuchungen
WO2002038734A2 (en) 2000-11-13 2002-05-16 Cistem Molecular Corporation Methods for determining the biological effects of compounds on gene expression
US7981842B2 (en) 2001-06-08 2011-07-19 Panomics, Inc. Method for detecting transcription factor-protein interactions
JP4200100B2 (ja) 2001-11-07 2008-12-24 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
US20170198046A1 (en) 2002-02-13 2017-07-13 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/ antigen complexes and uses thereof
WO2004029247A1 (en) 2002-09-26 2004-04-08 Centre For Translational Research In Cancer Nuclear receptor transcriptional corepressor and uses thereof
US20070178537A1 (en) 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
CN102989009B (zh) 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
WO2005099745A2 (en) 2004-04-13 2005-10-27 Uab Research Foundation Gcp-170 fusion proteins and uses thereof
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
WO2006070941A1 (ja) 2004-12-28 2006-07-06 Tokyo University Of Science 蛍光分子プローブを用いた新規薬剤スクリーニング方法
US20070214509A1 (en) 2005-12-23 2007-09-13 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
CA2634821C (en) 2005-12-23 2016-05-03 Andrew Emili Method for the identification of macromolecule targets of analytes
ES2338392B1 (es) 2006-08-18 2011-02-28 Universidad De Salamanca Metodo para la identificacion de signos de disfuncion neuronal pre-neurodegenerativos.
US9470683B2 (en) 2010-01-29 2016-10-18 Ge Healthcare Bio-Sciences Ab Method for determination of aggregates
US20130109737A1 (en) 2010-02-09 2013-05-02 Richard A. Young Mediator and cohesin connect gene expression and chromatin architecture
US8563705B2 (en) 2010-05-12 2013-10-22 Mayo Foundation For Medical Education And Research Ribonucleic acid binding motif protein 20 sequence variants
WO2012006551A2 (en) 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
EP2630154A1 (en) 2010-10-20 2013-08-28 F.Hoffmann-La Roche Ag Methods and compositions for modulating the wnt pathway
WO2012162249A1 (en) 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions
US20140349938A1 (en) 2011-06-03 2014-11-27 President And Fellows Of Harvard College Methods of diagnosing and treating amyotrophic lateral sclerosis
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
US20150045330A1 (en) 2012-01-17 2015-02-12 Kyoto University Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor
JP6340366B2 (ja) 2012-07-31 2018-06-06 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 運動ニューロン疾患を診断および処置する方法
ES2762326T5 (es) 2012-10-15 2023-04-27 Ionis Pharmaceuticals Inc Métodos para modular la expresión de C9ORF72
EP2912178B1 (en) 2012-10-25 2020-06-17 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
HK1220233A1 (zh) 2013-03-15 2017-04-28 怀特黑德生物医学研究院 用於神经变性疾病的细胞性发现平台
KR101591265B1 (ko) 2014-03-28 2016-02-03 한남대학교 산학협력단 퇴행성 신경계 질환 치료제 스크리닝 방법
US20170233762A1 (en) 2014-09-29 2017-08-17 The Regents Of The University Of California Scaffold rnas
KR20170092543A (ko) 2014-11-07 2017-08-11 톨레로 파마수티컬스, 인크. 슈퍼-인핸서 부위에서 전사 조절을 표적화하는 방법
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3242938B1 (en) 2015-01-09 2020-01-08 Bio-Rad Laboratories, Inc. Detection of genome editing
KR101671020B1 (ko) 2015-04-10 2016-11-02 충북대학교 산학협력단 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물
EP3362564B1 (en) 2015-10-14 2020-07-01 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
GB201518477D0 (en) * 2015-10-19 2015-12-02 Isis Innovation Biomolecule separation and modification
KR102346785B1 (ko) 2016-05-30 2022-01-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 공동-분획에 의한 리간드 식별
US10533167B2 (en) 2016-06-09 2020-01-14 The Trustees Of Princeton University Optogenetic tool for rapid and reversible clustering of proteins
JP2019523242A (ja) 2016-07-01 2019-08-22 アラーキス セラピューティクス， インコーポレイテッド Ｒｎａ機能をモジュレートするための化合物および方法
ES2973215T3 (es) 2016-09-02 2024-06-19 Univ Keio Agente terapéutico para la esclerosis lateral amiotrófica y composición para el tratamiento
JP2018050605A (ja) 2016-09-30 2018-04-05 学校法人慶應義塾 筋萎縮性側索硬化症、及び前頭側頭型認知症の病態誘導人工合成遺伝子、及びこれを用いた病態モデル
US10303979B2 (en) 2016-11-16 2019-05-28 Phenomic Ai Inc. System and method for classifying and segmenting microscopy images with deep multiple instance learning
DK3565891T3 (da) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
WO2018158160A1 (en) 2017-02-28 2018-09-07 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
US10538756B2 (en) 2017-03-06 2020-01-21 The Trustees Of Princeton University Disordered protein-based seeds for molecular clustering
WO2018170794A1 (en) 2017-03-22 2018-09-27 Tsinghua University Mutant fus model for als
US11492617B2 (en) 2017-08-08 2022-11-08 Ionis Pharmaceuticals, Inc Compositions and methods for modulation of protein aggregation
US10526380B2 (en) 2017-10-26 2020-01-07 St. Jude Children's Research Hospital Fusion protein and nucleic acid molecule for light-dependent stress granule assembly
WO2019109017A1 (en) 2017-12-01 2019-06-06 The Trustees Of Princeton University Light-responsive fusion proteins for controlling binding to targets
GB201803724D0 (en) 2018-03-08 2018-04-25 Cambridge Entpr Ltd Methods
CA3094974A1 (en) 2018-03-23 2019-09-26 Whitehead Institute For Biomedical Research Methods and assays for modulating gene transcription by modulating condensates
JP6624468B2 (ja) 2018-04-18 2019-12-25 国立大学法人滋賀医科大学 Ｔｄｐ−４３の凝集体が蓄積する疾患を治療及び／又は予防するための化合物のスクリーニング方法
US12521412B2 (en) 2018-08-16 2026-01-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Nucleic acids and nucleic acid analogs for treating, preventing, and disrupting pathological polynucleotide-binding protein inclusions
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
EP3921650A1 (en) 2019-02-08 2021-12-15 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CA3140651A1 (en) 2019-05-15 2020-11-19 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN114667451A (zh) 2019-09-18 2022-06-24 露点治疗公司 用于鉴定调节与RBM20聚集体和/或Rbm20多肽相关的一种或多种特征的化合物的组合物、系统以及方法
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
US20230314443A1 (en) 2020-08-12 2023-10-05 Dewpoint Therapeutics, Inc. Methods of identifying interactions of a compound and a condensate, or a component thereof, and uses thereof
WO2022187202A1 (en) 2021-03-02 2022-09-09 Dewpoint Therapeutics, Inc. New condensate paradigms
WO2022187225A1 (en) 2021-03-02 2022-09-09 Dewpoint Therapeutics, Inc. Methods of identifying a condensate phenotype and uses thereof
US20240375024A1 (en) 2021-08-20 2024-11-14 Dewpoint Therapeutics, Inc. Methods of isolating a composition comprising a target molecule
US20260043792A1 (en) 2022-08-03 2026-02-12 Dewpoint Therapeutics, Inc. Methods of identifying selective condensate modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Compositional Control of Phase-Separated Cellular Bodies;Salman F. Banani;《cell》;第166卷(第3期);第651-663页 *
Mass spectrometry imaging and profiling of single cells;Eric J. Lanni;《JOURNAL OF PROTEOMICS》;20120801;第75卷(第16期);摘要 *
Salman F. Banani.Compositional Control of Phase-Separated Cellular Bodies.《cell》.2016,第166卷(第3期),摘要、第652页. *

Also Published As

Publication number Publication date
CN113424064A (zh) 2021-09-21
AU2020219368A1 (en) 2021-07-15
US12174198B2 (en) 2024-12-24
EP3921650A1 (en) 2021-12-15
US20200284801A1 (en) 2020-09-10
KR20210124374A (ko) 2021-10-14
US11493519B2 (en) 2022-11-08
US20230176067A1 (en) 2023-06-08
SG11202106690QA (en) 2021-07-29
JP7564110B2 (ja) 2024-10-08
JP2022519523A (ja) 2022-03-24
CA3127237A1 (en) 2020-08-13
WO2020163795A1 (en) 2020-08-13
IL285117A (en) 2021-09-30
US20250298031A1 (en) 2025-09-25
JP2024178423A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
CN113424064B (zh) 表征化合物的凝聚物缔合特征的方法及其用途
Maia et al. Employing flow cytometry to extracellular vesicles sample microvolume analysis and quality control
Sun et al. Single cell proteomics using frog (Xenopus laevis) blastomeres isolated from early stage embryos, which form a geometric progression in protein content
Alexovič et al. Microproteomic sample preparation
JP2021060405A (ja) 代表診断法
US20230314443A1 (en) Methods of identifying interactions of a compound and a condensate, or a component thereof, and uses thereof
Choi et al. Patch-clamp proteomics of single neurons in tissue using electrophysiology and subcellular capillary electrophoresis mass spectrometry
WO2019109077A1 (en) Nanoparticles and distinct exosome subsets for detection and treatment of cancer
Zhang et al. Subcellular peptide localization in single identified neurons by capillary microsampling mass spectrometry
CN114729941A (zh) 筛选凝聚物相关特异性的方法及其用途
Aweida et al. The AAA‐ATPase ATAD1 and its partners promote degradation of desmin intermediate filaments in muscle
Kitata et al. Robust collection and processing for label-free single voxel proteomics
Roulhac et al. Microproteomics: quantitative proteomic profiling of small numbers of laser-captured cells
Song et al. Spatiotemporal deciphering of dynamic the FUS interactome during liquid-liquid phase separation in living cells
Gandhimathi et al. Super‐resolution microscopy reveals focal organization of ER‐associated Y‐complexes in mitosis
EP3341736A1 (en) A method of detecting molecules in proximity to a target molecule in a sample
US20260002941A1 (en) Single-cell proteomics analysis of embryos
US20230167501A1 (en) Methods For The Identification Of UBQLN2-Mediated Amyotrophic Lateral Sclerosis (ALS)
Davis Spatially resolved proteomics of a human brain tumour
Rakowska et al. Peptidome analysis: tools and technologies
Villarreal Hyphenated Microfluidic and Maldi Mass Spectrometry Platform for Targeted Intracellular Protein Analysis
Pollard Lung cancer biomarker discovery using proteomic techniques
CN117178330A (zh) 鉴定凝聚物表型的方法和其用途
Jagannathan et al. Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease
Nomellini et al. Modern techniques for protein assessment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant